Discovery of New CDDO‐Imidazole Derivatives as Potential Antitumor Agents

View at publisher Summarise with VIRAT
Authors: Yu Li, Lingjie Zhang, Qunfeng Luo, Yanzi Li, Siqi Zhang, Jianghong Pei, Mingming Qi, Na Li, Li Chen
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In the search for new CDDOs (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid derivatives) with higher antitumor activity in vivo, thirty CDDO-imidazole derivatives (1-30) were designed and synthesized. Then, 8 was selected due to its superior anti-proliferative activity against three cancer cell lines (B16F10, A549, and HCT116) and its lower toxicity in zebrafish embryos compared to the other evaluated compounds. Further study found that 8 induced apoptosis in HCT116 cells by downregulating Bcl-2, upregulating Bax, and activating caspase-3 to kill cancer cells. Notably, 8 exhibited significant antitumor efficacy comparable to CDDO-Me (bardoxolone methyl), which had entered clinical trials. Taken together, 8 represents a promising candidate for the treatment of cancer and merits further study.

Fields of Study & Subjects

Natural product bioactivities and synthesis Heterocyclic Compound Synthesis and Bioactivity Bioactive Compounds and Antitumor Agents

Publication details

Journal / source
ChemMedChem
Volume
21
Issue
6
Pages
e202600008–e202600008
Publication date
27 March 2026
Language
EN